文献速递肝病

MELD 3.0对MASH肝硬化等待名单结局的影响

Impact of Model for End-Stage Liver Disease 3.0 on Waitlist Outcomes of Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis Among Liver Transplant Candidates.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-10-25

该回顾性队列研究基于美国器官共享数据库2016至2022年等待名单注册者,评估MELD 3.0对MASH肝硬化患者等待名单结局的影响。在MASH肝硬化中,从MELD-Na转换为MELD 3.0后65.4%被上调、11.2%被下调;上调与90天等待名单死亡率升高相关(HR 1.14),但未提高移植概率(HR 1.04)。

要点

  • MELD 3.0使多数MASH肝硬化患者优先级上调,但未增加移植机会。
  • 上调分类与90天等待名单死亡率升高相关(HR 1.14)。
  • 女性MASH患者上调后移植概率亦未改善。

核心结论

  • MELD 3.0重新分类了大部分MASH肝硬化患者(尤其女性),但未增加移植可及性,尽管预测死亡风险更高。
  • 研究提示MELD 3.0在MASH肝硬化中捕获临床风险仍存在残余差距,需前瞻性数据验证。

研究设计与样本

  • 回顾性分析美国移植受者科学登记系统/器官共享联合网络数据库。
  • 纳入2016年1月1日至2022年12月31日等待名单注册者,共44,037例,其中MASH肝硬化12,790例,非MASH肝硬化31,247例。
  • 中位随访时间2.63个月。

主要发现

  • MASH肝硬化患者从MELD-Na转换为MELD 3.0后,65.4%被上调分类,11.2%被下调分类。
  • 女性MASH肝硬化患者中,上调分类同样未转化为移植概率改善。

临床怎么用

  • 临床医生应认识到MELD 3.0可能未充分反映MASH肝硬化患者的移植获益风险,需结合其他因素评估等待名单管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis is rapidly growing as an indication for liver transplantation (LT). However, the impact of Model for End-stage Liver Disease (MELD) 3.0 on waitlist outcomes in this population is not established. This study assessed the impact of MELD 3.0 on waitlist outcomes of patients with MASH cirrhosis using the Scientific Registry of Transplant Recipients database. METHODS: This was a retrospective analysis of the Scientific Registry of Transplant Recipients/United Network for Organ Sharing database including LT waitlist registrants from January 1, 2016, to December 31, 2022. Primary outcomes were 90-day waitlist mortality and transplantation probability in patients with MASH vs non-MASH cirrhosis. RESULTS: Among 44,037 waitlist registrants, 12,790 had MASH cirrhosis and 31,247 had non-MASH cirrhosis. The median follow-up was 2.63 months. In MASH cirrhosis, 65.4% were up-categorized and 11.2% were down-categorized when transitioning from MELD-Na to MELD 3.0. Up-categorization was associated with higher 90-day waitlist mortality (hazard ratio, 1.14; 95% confidence interval, 1.05-1.24; P = .002) but not higher transplantation probability (hazard ratio, 1.04; 95% confidence interval, 0.98-1.09; P = .18). Among female patients with MASH cirrhosis, up-categorization similarly did not translate into improved transplant probability. CONCLUSIONS: Although MELD 3.0 reclassifies a substantial proportion of patients with MASH-particularly women-it does not appear to increase transplant access despite higher predicted mortality risk. These findings highlight residual gaps in how MELD 3.0 captures clinical risk in MASH cirrhosis and underscore the need for prospective data following its implementation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lim WH, Tan DJH, Mitra K, et al. Impact of Model for End-Stage Liver Disease 3.0 on Waitlist Outcomes of Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis Among Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2025. PMID: 41284513. doi:10.1016/j.cgh.2025.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。